Objective: To determine if the use of intraoperative hemostatic agents was a risk factor for post-operative adverse events within 30 days of patients undergoing hysterectomy.
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Harris ET aL. 60 000 hysterectomies. 2, 3 However, there is a paucity of data supporting the routine use of hemostatic agents during hysterectomy to reduce the need for post-operative transfusions beyond traditional mechanical and electric-cautery techniques. Further, these agents add costs to each procedure and could be associated with adverse events requiring hospital re-admission, antibiotic administration, and re-operation. [4] [5] [6] [7] [8] [9] [10] [11] Therefore, the aim of the present study was to estimate, among patients undergoing hysterectomy, the effect of hemostatic agents on post-operative blood transfusion rates, pelvic abscess diagnoses, hospital re-admissions, and re-operations.
| MATERIALS AND METHODS
A retrospective cohort study included data from the Michigan Surgical Quality Collaborative (MSQC) database, a large, observational, multi-center clinical database of surgical and post-operative care in
Michigan, USA. Data in the MSQC database from patients who underwent a hysterectomy for any indication between January 1, 2013
and December 31, 2014 were included in the study; patient data were excluded if there were any missing covariate data. The study included de-identified patient records and the University of Michigan institutional review board granted "Not Regulated" status to the study (HUM00073978).
The MSQC is a Blue Cross Blue Shield of Michigan/Blue Care
Network-funded database voluntarily populated by both academic and community hospitals throughout Michigan, USA. At the time the present study was conducted, data from 52 participating hospitals were available for analyses. At each site, data were abstracted from medical records by trained nurse abstractors. Patient characteristics, intra-operative processes of care, and 30-day post-operative outcomes from hysterectomy procedures at contributing hospitals were routinely collected. To reduce sampling error, a standardized data collection methodology was employed using only the first 25 surgical procedures of an 8-day cycle. Detailed methods of the registry's data collection have been described previously.
12,13
The primary outcome variable was the presence of the major post-operative adverse events blood transfusion, diagnosis of pelvic abscess, hospital re-admission, and re-operation within 30 days of initial surgery. Post-operative blood transfusion was defined as the transfusion of any number of packed red blood cells after the primary surgery. Post-operative hospital readmission was defined as an inpatient hospital re-admission. Pelvic abscess diagnosis was defined as a surgical site infection in the organ space recorded in the patient's medical records. Post-operative re-operation was defined as any postoperative surgical operation for any indication, other than the completion of cancer staging. 
| RESULTS
There were 18 302 hysterectomies recorded during the study period;
202 (1.1%) were excluded because the surgeries were not performed by a gynecologist and 140 (0.8%) were excluded owing to incomplete covariate data. Consequently, the full study cohort included 13 301 patients who did not receive hemostatic agents and 4659 who did (Fig. 1 ). There were 13 974 patients included in the propensity score matched cohort, including 9316 (66.7%) patients who did not receive a hemostatic agent and 4658 (33.3%) patients who did. Among the full study cohort, patients who received hemostatic agents were more likely have fibroids (P<0.001), to have undergone robotic surgery (P<0.001), and to experience an estimated blood loss of at least 250 mL (P<0.001). After propensity score matching, the cohort was found to be closely matched across all characteristics (Table 1 ).
The overall prevalence of post-operative blood transfusion was
2.7% (95% CI 2.5-3.0). The logistic regression model demonstrated
no association between the use of hemostatic agents and the predicted prevalence of blood transfusion (P=0.291) ( Table 2 ). This was consistent with the estimate from the propensity score matched cohort (P=0.764).
The overall prevalence of pelvic abscess was 1.0% (95% CI 0.9- The outcomes of interest were also analyzed in terms of the surgical approach used during hysterectomy. Among surgeries performed using vaginal and abdominal approaches, no differences were observed in transfusions, pelvic abscesses, re-admissions, or re-operations between patients who received hemostatic agents and those who did not. The use of hemostatic agents during robotic-assisted laparoscopic procedures was associated with a greater incidence of predicted blood transfusions (P=0.019), pelvic abscess diagnoses (P=0.001), hospital re-admissions (P=0.001), and re-operations (P=0.021) ( Table 3 ). In laparoscopic hysterectomy procedures, the use of hemostatic agents was associated with an increase in predicted re-admissions (P=0.045) and predicted re-operations (P=0.046).
| DISCUSSION
The present study confirmed previous findings of associations between hemostatic agents and post-operative adverse events among patients who have undergone hysterectomies. In this retrospective study that examined hysterectomies performed for any indication from a statewide database in the USA, no benefit was observed for the use of hemostatic agents in terms of reduced blood transfusions, and increased risks for hospital re-admission and re-operation were recorded when hemostatic agents were used.
Hemostatic agents are designed to improve intra-operative and post-operative hemostasis, decreasing surgical and post-surgical adverse events such as requiring blood transfusions, the formation of post-operative hematomas, and re-operations. [15] [16] [17] [18] [19] In the present cohort, they were used in approximately 26% of all hysterectomy
procedures. This high rate of use suggests that they are used both to achieve hemostasis and as a prophylactic measure. Further, this high rate of utilization should be scrutinized in terms of evidence of a specific need in addition to evidence of an absence of harm. Previous studies supporting these benefits in hysterectomy are lacking, 4-11 and the present analysis, confirming findings of previous studies, identified that these agents could be harmful.
There are multiple possible reasons why hemostatic agents could be associated with post-operative adverse events of hysterectomies.
Hemostatic agents could provide inferior hemostasis in the hours and days following surgery compared with traditional hemostatic methods. Increased post-operative bleeding, even in small amounts, could lead to appreciable hematomas, in turn increasing the risk for pain through mass effects or inflammatory cytokines, or for infection by acting as a medium for the growth of bacteria; all of these could result in emergency department visits and re-admission. 1 Further, the presence of these foreign materials could cause persistent fluid collection that eventually becomes symptomatic, leading to re-admission. [6] [7] [8] [9] [10] [11] Hospital re-admissions are used as a target for quality improvements and reimbursement oversight. 
4-11
Previous studies in smaller cohorts have reported similar findings regarding associations between hemostatic agents and pelvic abscesses. 4, 5 Anderson et al. 5 found an increased risk of pelvic abscess after the use of a gelatin-thrombin matrix, as well as with oxidized regenerated cellulose. In the present study, the use of hemostatic agents was only associated with the diagnosis of pelvic abscess in robotic-assisted hysterectomies. This could result from a reliance on bipolar cautery and hemostatic agents to control surgical bleeding, compared with a variety of methods used during traditional hysterectomies. Additionally, the robotic-assisted hysterectomy data had the greatest statistical power and consequently, was better placed to detect a statistically significant result compared with the other analyses of individual surgical approaches. Of note, the causes for re-admission in the present cohort were frequently fever and infection. These indications for admission could be due to other infectious etiology, such as urinary tract infections, pneumonia, or superficial surgical site infections; however, it is also possible that these more general billing codes could actually represent pelvic abscess symptoms. Owing to this, pelvic abscess could be a systematically under-attributed cause of re-admission in billing or nurse-abstracted data.
Hemostatic agents are used widely in gynecologic surgery and their use is increasing. 3 In addition to their lack of proven benefit, these agents are expensive. In a report from one academic center in 2014, 15 the cost was identified as being between US$60 and $972 per agent per surgery. Assessing the benefits and harms of using hemostatic agents is important to patients, surgeons, and payers. Further, the costs of re-admission significantly increase the total costs that could be attributed to the use of these agents.
There were limitations to the present study. Even when multivariable regression and propensity score matching is used, it is susceptible to unmeasured confounder bias, as measured and unmeasured confounding can cause overestimation of effect sizes. Known confounders were tested and controlled for but there could have been other unmeasured confounders that were not adjusted for, including surgeon experience, skill, or measures of hospital quality, that could have been associated with hospital-level use of hemostatic agents. The analyses attempted to control for the surgical difficulty of the procedures by T A B L E 3 Estimated incidence of post-operative adverse events in the propensity score cohort among different surgical approaches. Hemostatic agent used 9.1 (7.6-10.7) 2.9 (1.2-4.5) 1.1 (0.7-1.6) b demonstrating a clear benefit to their use in hysterectomy, hemostatic agents should be used judiciously given the possible increased risk of post-operative adverse events.
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